Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

TLK286

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

Phase 2 Study of TLK286 in Metastatic Breast Cancer

Telik

Gail Brown, M.D. Chief Medical Officer

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

All Drugs and Chemicals

Doxorubicin

Liposomal doxorubicin

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Symptoms and General Pathology

Recurrence

Carboplatin

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Paclitaxel

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²

carboplatin

paclitaxel

The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

1. To determine the MTD of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin
2. To determine the safety of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin
3. To determine the objective response rate (ORR) of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Mantle Cell Lymphoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Patients with relapsed or refractory mantle cell lymphoma

Patients with relapsed or refractory diffuse large B cell lymphoma

Patients with relapsed or refractory multiple myeloma

30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks

Canfosfamide HCl for injection

Joseph Bertino, MD

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)

Disease will be assessed every 6 weeks using International Working Group Response Criteria for Non-Hodgkins Lymphoma in the mantle cell and diffuse large B cell lymphoma patients and the International Myeloma Working Group Response Criteria for multiple myeloma patients. Patients will continue to be treated and disease assessed until disease progression or unacceptable toxicity.

Duration of response will be determined after disease progression is documented in patients who have an objective response.

Toxicity will be assessed throughout study using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase 2 Study of TLK286 in Metastatic Breast Cancer	NCT00035841	Breast Neoplasm...	TLK286	18 Years -	Telik
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer	NCT00052065	Ovarian Neoplas...	TLK286	18 Years -	Telik
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer	NCT00040638	Carcinoma, Non-...	TLK286	18 Years -	Telik
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer	NCT00051948	Ovarian Neoplas...	TLK286	18 Years -	Telik
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer	NCT00051948	Ovarian Neoplas...	TLK286	18 Years -	Telik
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer	NCT00038428	Ovarian Neoplas...	TLK286	18 Years -	Telik
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer	NCT00088556	Carcinoma, Non-...	TLK286 carboplatin paclitaxel	18 Years -	Telik
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma	NCT01148108	Mantle Cell Lym... B Cell Lymphoma Multiple Myelom...	Canfosfamide HC...	18 Years -	Telik

Spots Global Cancer Trial Database for tlk286

Every month we try and update this database with for tlk286 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tlk286

Every month we try and update this database with for tlk286 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tlk286 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.